Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the second quarter of 2023.
June quarter revenues grew 11% year-over-year to $3.16 billion. Net product sales, which account for more than 50% of total revenues, edged up 1%.
Adjusted earnings moved up 5% to $10.24 per share in Q2 from $9.77 per share in the same period of 2022. Unadjusted profit was $968 million or $8.50 per share, compared to $852 million or $7.47 per share last year.
“We remain focused on advancing our robust pipeline at all stages, and we were pleased to announce positive data from a late-stage study of Dupixent in COPD and make continued progress with our costimulatory and bispecific antibody candidates in oncology,” said the company’s CEO Leonard Schleifer,” said the company’s CEO Leonard Schleifer.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
McCormick & Company, Incorporated (NYSE: MKC) reported third quarter 2023 earnings results today. Net sales increased 6% year-over-year to $1.68 billion, but narrowly missed estimates of $1.70 billion. Net income
Shares of Carnival Corporation & plc (NYSE: CCL) were down on Monday. The stock has gained 69% year-to-date. The company delivered strong results for the third quarter of 2023 and although
Over the years, brand loyalty and diversification of the portfolio have played a key role in the continued success of PepsiCo, Inc. (NASDAQ: PEP) The soft drink giant is now